Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083902 · ClinicalTrials.gov registry record · Phase 2
Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT00083902 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 190 participants.
The verdict
NCT00083902, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
The purpose of this investigational trial is to find out how well patients respond and how long their response lasts when treated with a standard regimen of dexamethasone with or without thalidomide and also find out what kind of side effects patients will experience.
Interventions
- DRUG Dexamethasone
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 1998-06 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083902
The ClinicalTrials.gov registry entry for NCT00083902 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT00083902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083902 about?
NCT00083902 is a clinical study titled "Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy". The purpose of this investigational trial is to find out how well patients respond and how long their response lasts when treated with a standard regimen of dexamethasone with or without thalidomide and also find out what kind of side effects patients will experience.
What is the current status of trial NCT00083902?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 1998-06. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00083902?
The interventions under investigation include: Dexamethasone (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00083902?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.